Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2023)

Standard Biotools (LAB) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $173000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Amortization of Deferred Charges fell 14.36% to $173000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $770000.0, a 7.23% decrease, with the full-year FY2023 number at $770000.0, down 7.23% from a year prior.
  • Amortization of Deferred Charges was $173000.0 for Q4 2023 at Standard Biotools, down from $187000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $2.0 million in Q1 2019 to a low of -$194000.0 in Q4 2019.
  • A 5-year average of $247631.6 and a median of $187000.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: crashed 107.28% in 2019, then skyrocketed 168.35% in 2022.
  • Standard Biotools' Amortization of Deferred Charges stood at -$194000.0 in 2019, then surged by 167.01% to $130000.0 in 2020, then skyrocketed by 51.54% to $197000.0 in 2021, then grew by 2.54% to $202000.0 in 2022, then fell by 14.36% to $173000.0 in 2023.
  • Per Business Quant, the three most recent readings for LAB's Amortization of Deferred Charges are $173000.0 (Q4 2023), $187000.0 (Q3 2023), and $206000.0 (Q2 2023).